Global Digital Pathology Market is estimated to be valued at US$ 884.4 million in 2023 and is expected to exhibit a CAGR of 12.2% during the forecast period (2023-2030). Increase in product launches by market players is expected to drive the market words over forecast period. Moreover, increase in number of government initiatives is expected to drive the market growth.
Analysts’ Views on Global Digital Pathology Market :
Increasing number of product launches by market players can boost the market growth over forecast period. For instance, in November 2022, Nucleai, Inc., a software and AI-powered spatial biology solution providing company, launched the new generation of multiplex immunofluorescence (mIF) analysis system. The newly launched multiplex immunofluorescence (mIF) analysis system provides increased levels of speed and accuracy for drug discovery and development.
Figure 1. Global Digital Pathology Market Share (%), By Product Type, 2023
Global Digital Pathology Market- Driver
Rising Government Initiatives
Increasing initiatives by government bodies such as loosening restrictions on digital pathology software-hardware approvals and others is expected to offer lucrative growth opportunities. For instance, in April 2020, the U.S. Food and Drug Administration (FDA) issued a waiver permitting pathologists to perform primary readings from their homes and loosening restrictions on software-hardware approvals. This resulted in an increase of digital clinical pathology implementation.
Increasing Technological Advancements in Digital Pathology Systems
Digital pathology offers a better viewing experience, which enhances analysis. This lowers diagnostic error rates. These tools additionally provide service providers immediate access to earlier cases for comparison. These advanced systems store data for use in long-term predictive analysis. Specimens are barcoded to reduce the chance of misidentification. Also, this removes concerns about lost data due to slide breakage. Increasing technological advancements in digital pathology systems is expected to drive the market growth over the forecast period. For instance, according to an article published by Visceral Medicine Journal in 2021, digital pathology has technological advancement from artificial intelligence to label-free imaging. The use of artificial intelligence in digital pathology is growing along with the development of slide scanners, the abundance of data produced, and ever-increasing computing power.
Figure 2. Global Digital Pathology Market Share (%), By Region, 2023
Global Digital Pathology Market - Regional Analysis
Among regions, North America is expected to dominate the market over the forecast period. The key drivers that are expected to propel the North America digital pathology market growth include the need for improving efficiency and accuracy of pathological diagnosis alongside the higher demand for remote work. As stated by Margaretta Colangelo, an advisory board member of the AI Precision Health Institute at the University of Hawaiʻi Cancer Center, in May 2022, the number of pathologists in North America is 4X less than what is needed on a global scale.
Europe is expected to hold second position in Global Digital Pathology Market over the forecast period. Europe is among the early adopters of digital pathology. One of the key drivers of its adoption in the region is that digital pathology supports collaborative research. Digital pathology provides access to large datasets & pathological images even from remote locations. This has encouraged several organizations to collaborate for adoption of a common digital platform. For instance, in 2020, the Deutsches Krebsforschungszentrum (DKTK) also known as the German Cancer Consortium, launched a Joint Imaging Platform (JIP) in the radiology and nuclear medicine departments of 10 university hospitals in Germany for feasible and shared analysis of pathological images.
Global Digital Pathology Market- Impact of Coronavirus (COVID-19) Pandemic
According to World Health Organization (WHO), Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Till January 16, 2023, worldwide 663,640,386 people were affected.
The COVID-19 had a positive impact on the global digital pathology market, as many pharmaceutical and medical device companies were focusing on developing image analysis software and slide scanners for digital pathologies. Thus, increasing launches of new digital diagnostic system during the pandemic, aided in the growth of global digital pathology market. For instance, in November 2020, 3DHISTECH Ltd., a software company based in the U.K., launched new digital diagnostic system named PANNORAMIC pathology diagnostic system, which aids to fulfill special requirements of routine pathology. The PANNORAMIC pathology diagnostic system is a new integrated digital pathology solution that enables the pathologist to deliver a quick diagnosis.
|Base Year:||2022||Market Size in 2023:||US$ 884.4 Mn|
|Historical Data for:||2017 to 2021||Forecast Period:||2023 to 2030|
|Forecast Period 2023 to 2030 CAGR:||12.2%||2030 Value Projection:||US$ 1,977.9 Mn|
Leica Biosystems Nussloch GmbH, Olympus Corporation, F. Hoffmann-La Roche Ltd., Merck KGaA, GE Healthcare, Mikroscan Technologies, Inc., Koninklijke Philips N.V., Sectra AB, Propath UK Limited, Inspirata, Inc., Hamamatsu Photonics, Inc., OracleBio Limited, MD Biosciences, Aiforia, Xybion Digital Inc., Nucleai, Inc
|Restraints & Challenges:||
Global Digital Pathology Market Segmentation:
The Global Digital Pathology Market report is segmented into Product Type, Therapeutic Area, Technology, End User and Region
Based on Product Type, the market is segmented into, Image Analysis Software, Scanner, Services. Out of which, image analysis software segment is expected to dominate the global digital pathology market during the forecast period and this is attributed due to increasing product launches
Based on Therapeutic Area, the market is segmented into oncology, Hematology, Autoimmune Disorders, Dermatology and others. Out of which, oncology segment is expected to dominate the market over the forecast period and this is attributed due to increasing usage of digital pathology in various cancer/tumor types.
Based on Technology, the market is segmented into Immunohistochemistry, ISH & FISH, Immunofluorescence and Others. Out of which, Immunohistochemistry segment is expected to dominate the market over the forecast period and this is attributed due to increasing research and development activities.
Based on End User, Global Digital Pathology Market is segmented into Pharmaceutical and Biotechnology Companies, Diagnostic Labs, Hospital Laboratories and Others. Pharmaceutical and Biotechnology Companies segment is expected to dominate the market over the forecast period and this is attributed to the increasing product launches by pharmaceutical and biotechnology companies operating in the market.
Based on Region, Global Digital Pathology Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa. North America is expected to dominate the market over the forecast period and this is attributed to the increase in number of product approvals from regulatory authorities.
Among all segmentation, product type segment has highest potential due to increasing product launches by market players. For instance, in October 2021, PerkinElmer, Inc., a life-science research, and food, environmental, and industrial testing company, launched the Signals Image Artist software, a next-generation cell image analysis software. Signals image artist software is used in the management platform of drug discovery research.
Global Digital Pathology Market Cross Sectional Analysis:
Among product type segment, Scanner held as a dominant segment in 2023 in North America region due to increasing product launches. For instance, in June 2022, F. Hoffmann-La Roche Ltd, a pharmaceutical company, announced the launch of the next-generation VENTANA DP 600 slide scanner with CE-IVD mark (Conformité Européenne-in vitro diagnostic mark). This newly launched slide scanner produces clear image of stained histology slides from patient tissue samples. It also provides ease-of-use and workflow flexibility to pathology lab workers.
In therapeutic area segment, oncology segment is dominant in North America region due to increasing incidence of cancer. For instance, in December 2022, according to the article published by the National Center for Biotechnology Information, the number of cancer cases in India for the year 2022 were estimated to be 14,61,427 (crude rate:100.4 per 100,000).
Global Digital Pathology Market: Key Developments
In September 2022, Scopio Labs, a company advancing digital microscopy, launched the Full-Field Bone Marrow Aspirate (FF-BMA) application platform. This platform is the first to allow a complete digital workflow for bone marrow aspirate scanning and analysis. The highresolution full-field imaging and AI-driven decision support system from Scopio bring hematopathology one step closer to the much-needed digital transformation.
On October 18, 2022, GE Healthcare, a manufacturing company, and Tribun Health, a software company, announced a partnership with the goal of delivering departmental digital pathology solutions that give healthcare professionals a more comprehensive understanding of patient records. The alliance intends to bring a data management solution by interfacing Tribun’s Health Suite data into GE Healthcare’s solution, such as GE Healthcare’s vendor neutral archive, Edison Datalogue.
In April 2022, Scopio Labs, a company advancing digital microscopy, announced the launch and CE Mark (Conformité Européenne) approval of X100 Full Field Peripheral Blood Smear (Full Field PBS) all-digital morphology analysis platform, which is the first digital microscope that allows remote consultation and includes a computer-vision based decision support system, advancing manual microscopy into the digital age.
In May 2022, OptraSCAN India Private Limited, a company that provides the digital pathology solutions, announced that its digital pathology scanner OS-SiA had been granted U.S. patent-No 2020/0334814 A1 by the United States Patent and Trademark Office. With its built-in intelligence, OS-SiA can simultaneously scan, index, and analyze abnormal samples. The end user will benefit from being able to overlay the results of the analysis over the entire slide image that has been scanned.
Global Digital Pathology Market: Restraint
High cost of digital pathology system
The use of digital pathology for routine diagnoses is rapidly expanding, but its widespread application is difficult from a financial standpoint. According to an article published in July 2022 by the National Center for Biotechnology Information, significant financial investments are needed for digital pathology, which may be affordable for high-income nations but are prohibitively expensive for many low- and middle-income nations. Despite the wide range of mentioned pricing for each device, a single high-throughput scanner will cost between US$ 100,000 and US$ 400,000. Additional expenses come from hardware (high-resolution displays and powerful computers), additional software, IT infrastructure, and staff.
Global Digital Pathology Market: Key Players
Major players operating in the global digital pathology market include Leica Biosystems Nussloch GmbH, Olympus Corporation, F. Hoffmann-La Roche Ltd., Merck KGaA, GE Healthcare, Mikroscan Technologies, Inc., Koninklijke Philips N.V., Sectra AB, Propath UK Limited, Inspirata, Inc., Hamamatsu Photonics, Inc., OracleBio Limited, MD Biosciences, Aiforia, Xybion Digital Inc., Nucleai, Inc.
*Definition: Digital pathology is a branch of pathology that focuses on data management using data generated from digitized specimen slides. Digital pathology employs virtual microscopy through the use of computer-based technology.
Digital pathology is the process of digitizing glass slides using a whole slide image scanner and then analyzing the digital images using an image viewer, typically on a computer monitor or mobile device. Digital pathology offers a better viewing experience, which enhances analysis. This lowers diagnostic error rates. These tools additionally provide service providers immediate access to earlier cases for comparison. These advanced systems store data for use in long-term predictive analysis. Specimens are barcoded to reduce the chance of misidentification. Also, this removes concerns about lost data due to slide breakage. In the modern world, digital pathology has many benefits including improved disease diagnosis accuracy, quicker recovery times, increased pathologist productivity, and so on. As a result of these benefits, healthcare facilities are increasingly using digital pathology platforms for disease diagnosis, and major market players are getting involved in product launch process.
The use of new technologies for the development of innovative digital pathology platform is expected to drive the growth of the global digital pathology market over the forecast period. For instance, in June 2022, Tribun Health, a software company, launched TeleSlide Patho 5, an online telepathology platform which is utilized for sharing digital pathology slides and other multimedia documents.
Increasing number of partnerships by the market players is expected to drive the market growth over forecast period. For instance, on September 23, 2022, Paige AI, Inc., a provider of digital pathology solutions and clinical AI applications, and OptraScan, a producer of whole slide scanners, announced a partnership to streamline the adoption of digital pathology technology in the U.S., European Union countries, and U.K. The companies’ goal is to lower obstacles to glass pathology slide digitization, which will improve oncology and pathology workflows.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients